CCCC Q4 2023 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+14.3% YoY

Gross Profit

$2M48.1% margin

Operating Income

-$37M-1147.7% margin

Net Income

-$35M-1065.7% margin

EPS (Diluted)

$-0.68

QoQ Revenue Growth

-70.5%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$376M

Total Liabilities

$130M

Stockholders' Equity

$246M

Cash & Equivalents

$127M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+14.3%
Gross Profit	$2M	-$28M	+105.6%
Operating Income	-$37M	-$38M	+2.3%
Net Income	-$35M	-$37M	+6.5%